Literature DB >> 6798060

Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine.

A Rösler, Y Litvin, C Hage, J Gross, E Cerasi.   

Abstract

A family of three generations is described in which six females had hyperthyroidism secondary to chronic overstimulation of the thyroid by pituitary TSH. In the untreated state, their basal levels of T4 ranged between 14-22 microgram/dl, T3 levels ranged from 205-300 ng/dl, T3 resin uptake ranged from 43-61%, TSH ranged from 5-26 microU/ml, and PRL ranged from 33-75 ng/ml. Basal metabolic rate (BMR) was elevated in all patients (+32 to +100%). There was no evidence of pituitary tumor, In spite of elevated circulating thyroid hormones, TRH stimulated TSH and PRL to 25-57 microU/ml and 120-300 ng/ml, respectively. Serum TSH could be suppressed to normal after 1 week of T3 administration (25 microgram three times per day). Concomitantly, serum T3 and T4 levels fell, and the TSH response to TRH became normal. In contrast, T4 (200 microgram/day) administered for 1 and 4 weeks, respectively, to two patients did not suppress the pituitary-thyroidal axis. A long term therapeutic trial was performed in three patients with T3 and a single morning dose of 25-50 microgram. TSH gradually returned to normal, as did thyroid hormone levels and the BMR. The clinical manifestations of hyperthyroidism regressed, and complete remission was achieved after 2-3 months of T3 therapy, which persists to data as long as medication is continued. The inappropriate TSH secretion of our patients appears to be due to partial unresponsiveness of the thyrotroph to thyroid hormone. It is suggested that either the pituitary T4 monodeiodinase is deficient in our patients, resulting in low intracellular T3 levels, or the thyrotroph has reduced sensitivity to T3 and therefore can shut off TSH only when serum T3 is raised to high levels, albeit intermittently.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6798060     DOI: 10.1210/jcem-54-1-76

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Resistance to thyroid hormone.

Authors:  R E Weiss; S Refetoff
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

2.  Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotrophin secretion.

Authors:  A W Chan; I A MacFarlane; C van Heyningen; P M Foy
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

3.  Hyperthyroidism due to familial pituitary resistance to thyroid hormone: successful control with 3, 5, 3' triiodothyroacetic associated to propranolol.

Authors:  M Aguilar Diosdado; L Escobar-Jimenez; M L Fernandez Soto; A Garcia Curiel; F Escobar-Jimenez
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

4.  Myasthenia gravis and hyperthyrotropinemia in a child.

Authors:  S M Scott; A H Klein; J A Brasel
Journal:  West J Med       Date:  1987-04

5.  Anti-iodothyronine autoantibodies in a girl with hyperthyroidism due to pituitary resistance to thyroid hormones.

Authors:  A Crinò; P Borrelli; R Salvatori; D Cortelazzi; R Roncoroni; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

6.  A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds.

Authors:  S J Usala; G E Tennyson; A E Bale; R W Lash; N Gesundheit; F E Wondisford; D Accili; P Hauser; B D Weintraub
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia--a case report and review of the literature.

Authors:  I M Spitz; M Sheinfeld; B Glasser; H J Hirsch
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

8.  Congenital hypothyroidism and partial thyroid hormone unresponsiveness of the pituitary in a patient with congenital thyroxine binding albumin elevation.

Authors:  S L Drop; E P Krenning; R Docter; S M de Muinck Keizer-Schrama; T J Visser; G Hennemann
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

9.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).

Authors:  P Beck-Peccoz; G Piscitelli; M G Cattaneo; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

10.  Abnormal daily periodicity of serum thyrotropin (TSH) and evidence for defective TSH suppression in a case of non-neoplastic syndrome of inappropriate TSH secretion.

Authors:  S Benvenga; G A Sobbrio; F Vermiglio; L Li Calzi; S Cannavò; F Consolo; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.